晴時多雲

頂尖醫學期刊將我列中國一省 副總統與中研院士聯名要求更正

副總統陳建仁在臉書發文,將要求《The Lancet》更正。(資料照)

副總統陳建仁在臉書發文,將要求《The Lancet》更正。(資料照)

2019/06/29 13:21

〔記者吳亮儀/台北報導〕頂尖醫學期刊《The Lancet》(刺胳針)在25日刊登一篇中國的公共衛生研究,將我國列為中國一省,引發大批台灣網友抗議;副總統陳建仁昨深夜也在臉書發文,將和多名中研院院士一起致函《The Lancet》編輯部,要求該期刊立即更正錯誤。

這篇中國的論文內容為探討中國的非傳染性疾病,包括心臟病、肺癌、中風等,以各省的疾病負擔和風險因子納入系統性分析,但圖表中都把台灣納入中國一省。

陳建仁指出,《The Lancet》編輯部雖回應這是根據聯合國(UN)和世界衛生組織(WHO)的方針,才將台灣列為中國一省,和其它的國際衛生分析沒有不同。

但陳建仁說,他要嚴正指出,除了政治上的錯誤外,因為台灣和中國為各自獨立的兩個不同國家,有各自獨立不同的行政、健保體系,在健保相關資料的完整性與正確性上,台灣與中國更是有許多差異,因此,這篇研究將不同方法所蒐集的健康資料放在同一個層級的模型來作研究,不但產生許多方法學上與研究結果的偏差,更已犯了學術研究的大忌,「我們認為頂尖的《The Lancet》期刊不應該犯這樣的錯誤才對」。

陳建仁說,他將和中央研究院陳定信院士、廖運範院士、楊泮池院士等人,聯名致函《The Lancet》編輯部,要求該期刊立即更正錯誤,「因為,這不只關係到台灣的主權尊嚴,更關係著國際學術研究的專業與倫理」。

陳建仁是國際知名流行病學家,是美國約翰.霍普金斯大學博士,當選世界科學院院士、美國國家科學院海外院士、中研院院士、中研院副院長,對於公共衛生領域非常專精。

陳建仁致函《The Lancet》編輯部全文:

To the Editor:

We read the recent article by Zhou et al. comparing mortality, morbidity and risk factors in China and its provinces, 1990-2017. The authors used data from Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 to analyse health patterns in 34 province-level administrative units in China. This is a misleading and biased report due to the inclusion of Taiwan in the analyses.

The authors made an obvious flaw by including Taiwan in the study. The national health system, government system and administrative system are independent in Taiwan. The completeness and accuracy of national databases of health insurance, cancer registry, death certification, cancer screening and health surveillance in Taiwan is totally different from those of China. The health outcomes measured by different methods should not be included in the same hierarchical models. Taiwan has its own cancer and death registration system, and the information were not collected by the Chinese Center for Disease Control and Prevention as described wrongly in the article. The data source from the Global Health Data Exchange (http://ghdx.healthdata.org/countries) that the authors used in this paper also clearly showed Taiwan and China are two distinguished countries under the category of Eastern Asia.

Taiwan has an independent National Health Insurance system which covers more than 95% of 23 million people since 1995. Taiwan has also implemented a series of public health programs to reduce mortality and morbidity which are not implemented in China. For example, Taiwan is the first country in the world to implement universal newborn hepatitis B vaccination program since 1984 whereas China started in 1992. We reimbursed antiviral treatment for chronic viral hepatitis since 2003 and decreased liver disease burdens continuously. Taiwan started to reimburse direct antiviral agents for chronic hepatitis C patients with advance fibrosis since 2017 and for all chronic hepatitis C patients since 2019, and has committed to eliminating hepatitis C infection in 2025, 5 years earlier than the 2030 deadline set by WHO.

The inclusion of Taiwan in the analysis leads definitely to a significant bias of the findings of Zhou et al. In their similar publication in 2016 (Lancet 387:251-272), Taiwan was not included in the analyses. We would like to urge the authors to re-run the analyses and remove Taiwan from their analyses in order to yield unbiased estimates of mortality, morbidity and risk factors in China. Lancet, as an esteemed medical journal, has the reputation to publish accurate and precise research findings. Such a major categorization mistake in the methods section by Zhou et al. should be rectified.

Maggie Dai-Hua TSAI RIEDIKER

Mei-Hsuan LEE

Ding-Sing CHEN

Yun-Fan LIAW

Pan-Chyr YANG

Yi-Hao HUANG

Chien-Jen CHEN

陳建仁在臉書發文。(記者吳亮儀翻攝)

陳建仁在臉書發文。(記者吳亮儀翻攝)